BIO · Bio-Rad Laboratories, Inc.
AI read · Good for BIO
The AI's read
The higher target and unchanged rating show RBC sees more room for Bio-Rad's shares to rise. Bio-Rad's third-quarter sales and adjusted earnings also grew, supporting that view.
RBC Capital Markets increased its price target for Bio-Rad Laboratories from $390 to $440 after strong earnings and sales growth.
Good for BIO
RBC raised its target for Bio-Rad to $440 from $390 and kept its “Outperform” rating. The company also reported growth in adjusted earnings and sales, so the update is favorable.
Get alerts for BIO
Follow Bio-Rad Laboratories, Inc. (BIO) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for BIOFree on the App Store and Google Play, or on the web.